Severe acute respiratory syndrome
In 2020, the company signed a $135 million deal with Johnson &amp; Johnson to provide and reserve manufacturing capacity for J&amp;J's COVID-19 vaccine candidate for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus which causes COVID-19. Human testing began later that year, and the vaccine received Emergency Use Authorization from the FDA in February 2021.